A Phase 2 interventional study of Cannabis oil in ADHD, Hyperactivity and Attention Deficit, sponsored by Brlev Agricultural Crops Ltd. Terminated at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-25.
Sponsored by Brlev Agricultural Crops Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel — 9 open to participants now, 10 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Israel.
Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel, this one is the 60th largest by enrollment of the 61 interventional ones that give a count, is one of 4 that started in 2022, is one of 10 in phase 2, and was the 68th registered.
1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →9 of the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel are open now. Recruiting first, the newest first:
Adina Maeir · Sites in Israel
Women only · Healthy volunteers
Hebrew University of Jerusalem · Sites in Israel
Ages 18–60
Ben-Gurion University of the Negev · Sites in Israel
Ages 18–65
Loewenstein Hospital · Sites in Israel
Ages 15–18 · Men only
University of Haifa · Sites in Israel
Ages 20–60 · Healthy volunteers
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 4 · Phase 4 4
First in 2000; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 46 across the 61 interventional studies, 60 across the 23 observational. Of the 45 that completed or were terminated, 7 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 85 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Brlev Agricultural Crops Ltd as lead sponsor.
Brlev Agricultural Crops Ltd has 1 study filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
1 of the studies in Attention Deficit Disorder with Hyperactivity with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07105475Ben-Gurion University of the NegevTreatment of ADHD Using High and Low Frequency Paired Associative Deep Transcranial Magnetic Stimulation | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ADHD is the most frequent neuro-developmental disorder in childhood and often continues into adolescence and adulthood.
Indicated drug treatments for ADHD fall into 2 categories: stimulants (such as methylphenidate and amphetamines) and non-stimulants (such as atomoxetine, guanfacine and clonidine) but some persons cannot tolerate their secondary effects or find them non-effective.
In the last decade, medical cannabis products have been researched as possible treatment for neurological and mental diseases such as: Post trauma disorder (PTD), autism (ASD), epilepsy, fibromyalgia (FM) and more.
Data on the effects of cannabidiol rich cannabis extract use for ADHD seems promising but is still limited. The aim of this study is to investigate if oral cannabinoids given to adults with ADHD affect the symptoms of the disorder.
The main objectives of the study are: 1) to characterize the effects of treatment with cannabis oil on symptoms of ADHD; 2) to compare safety and efficacy of cannabis oil products with different CBD,Cannabidivarin (CBDV), cannabigerol (CBG) and THC ratio; 3) and to measure endocannabinoids, THC and CBD and metabolites levels in the blood of the participants.
In this study, participants diagnosed with ADHD will be treated with canabidiol-rich cannabis oil and will follow up weekly during approx.1 month (the study period). Blood tests will be performed before and after treatment. Blood tests include blood count, blood chemistry, hormones profile, phyto- and endo- cannabinoids and their metabolites. Test of Variables of Attention test (TOVA) will be administrated before and after treatment
Participants will be screened by study staff for ADHD diagnosis and failure of conventional treatment.
Participants passing the screening will undergo blood and urine tests, fill questionnaires, TOVA test and will be randomized to one of the 4 arms.
Participants will receive the drug, be instructed as per dose titration and as per danger of driving under drug influence.
Telephone follow up will take place weekly after 7 days from starting. Participants will guess to which arm the participant was allocated to after 2 weeks of treatment .
Participants will arrive for a last visit, fill questionnaires, do TOVA test and undergo blood and urine tests.
Participants will be contacted over the phone for a last time, after treatment completion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cannabis oil oral drops containing 95 mg/ml CBD; 5 mg/ml THC; 15 mg/ml CBDV ; no CBG, once daily Titration from 0.3 to 1.8 ml/day during 21 days
Drug: Cannabis oil
Cannabis oil oral drops containing no CBD; 5 mg/ml THC; no CBDV; 95 mg/ml CBG, once daily. Titration from 0.3 to 1.8 ml/day during 21 days
Drug: Cannabis oil
Cannabis oil oral drops containing 47.5 mg/ml CBD; 2.5 mg/ml THC; 7.5 mg/ml CBDV; 47.5 mg/ml CBG, once daily. Titration from 0.3 to 1.8 ml/day during 21 days
Drug: Cannabis oil
Placebo oil oral drops once daily. Titration from 0.3 to 1.8 ml/day during 21 days
Drug: Cannabis oil
administration of different cannabis oil types as compared with placebo
efficacy of cannabis oil on ADHD symptoms as per TOVA test
To assess if participants treated with cannabis oil show an improvement in TOVA scores
Time frame: 30-35 days
efficacy of cannabis oil on ADHD symptoms as per Conners questionnaire
To assess if participants treated with cannabis oil show an improvement in Conners score
Time frame: 30-35 days
to assess side effects and their severity using questionnaire
To examine whether cannabis oil side effects are tolerable and transient
Time frame: 60 days
number of participants who dropped-out
to check whether drop out percentage is similar among groups
Time frame: 60 days
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study protocol and Statistical Analysis Plan to be shared
Supporting information: Study protocol, Statistical analysis plan
Time frame: during all the trial
Access criteria: interested colleagues
Ran from Jul 2022 to primary completion in Dec 2022, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabis sativa flowering TOP
Attention Deficit Disorder with Hyperactivity →